SARS-CoV-2 vaccines are well tolerated in patients with mastocytosis

Tuncay, Gülseren; Bostan, Özge Can; Damadoğlu, Ebru; Karakaya, Gül; Kalyoncu, Alı Fuat

doi:10.1016/j.anai.2022.02.026

Cited by 6 publications

(6 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The rate of non-anaphylactic allergic reactions was 6.2%. Tuncay et al [12] reported that they administered a total of 15 doses of COVID-19 vaccine, 12 doses of Sinovac, and 3 doses of BioNTech to 6 adult patients diagnosed with mastocytosis. They observed that a patient with CM developed throat swelling, cough, and shortness of breath within 2 min after vaccination despite receiving premedication 1 h before the injection.…”

Section: Discussionmentioning

confidence: 99%

COVID-19 Vaccines Are Safely Tolerated in Adolescents with Cutaneous Mastocytosis

Bulut

Severcan

Ertuğrul³

2023

Int Arch Allergy Immunol

View full text Add to dashboard Cite

Introduction: The management of the COVID-19 vaccine in children with mastocytosis is unclear due to a lack of data. In the current study, we aimed to evaluate the adverse reactions following COVID-19 vaccination in adolescents with cutaneous mastocytosis (CM). Methods: This study included 27 paediatric patients who were diagnosed with CM and were followed up in the paediatric allergy department of a tertiary care children’s hospital. Results: The median (IQR) age of the patients at the time of COVID-19 vaccination was 180 (156–203) months. Forty-four per cent of patients were vaccinated with the COVID-19 vaccine. Among all participants, the vaccination rate was found to be higher in older children, those who had been diagnosed with MPCM, and those who had not been infected with COVID-19 (p = 0.019, p = 0.009, p = 0.002, respectively). A total of 23 doses of the COVID-19 vaccine, including two doses of Sinovac/CoronaVac and 21 doses of Pfizer/BioNTech, were administered to 12 paediatric patients with CM. One of the patients had a history of intense itch, erythematous urticarial plaques, and had an exacerbation of existing skin lesions within 24–48 h after both doses of Pfizer/BioNTech vaccination. Conclusion: The COVID-19 vaccination of patients with CM in this series seems to be safe, and the rate of adverse events was comparable to that in the general population. These results found in adolescents with CM are in line with the existing evidence that CM does not preclude vaccination in children.

show abstract

Section: Discussionmentioning

confidence: 99%

COVID-19 Vaccines Are Safely Tolerated in Adolescents with Cutaneous Mastocytosis

Bulut

Severcan

Ertuğrul³

2023

Int Arch Allergy Immunol

View full text Add to dashboard Cite

show abstract

“…There already are some reports of patients with mastocytosis who have safely received the COVID-19 vaccine. [7][8][9][10][11][12] Further studies and reports are needed to settle on the best approach to vaccinate these patients.…”

Section: Discussionmentioning

confidence: 99%

Mastocytosis: the safety of different COVID-19 vaccines

Nunes¹,

Tavares²,

Faria³

et al. 2022

AAAI

View full text Add to dashboard Cite

A pandemia por COVID-19 obrigou ao rápido desenvolvimento de vacinas para combate ao SARS-CoV-2. Após o início da vacinação começaram a surgir relatos de reações adversas às vacinas, incluindo reações anafiláticas, surgindo dúvidas sobre a segurança das vacinas em doentes com mastocitose. Os autores apresentam a sua experiência em relação à administração de diferentes vacinas contra a COVID-19 em doentes com diagnóstico de mastocitose.Descritores: COVID-19, vacinas contra COVID-19, mastocitose, hipersensibilidade a vacinas, pré-medicação.The COVID-19 pandemic has forced the development of vaccines to fight SARS-CoV-2. After vaccination began, reports of adverse reactions, including anaphylaxis, emerged. This raised concerns about the safety of COVID-19 vaccines in patients diagnosed with mastocytosis. The authors share their experience in administering different COVID-19 vaccines to patients diagnosed with mastocytosis.

show abstract

“…However, in the first few months, some cases of vaccines-related hypersensitivity reactions were observed [ 7 ] and worries about the safety of COVID-19 vaccines emerged [ 2 ]. This led to a slowdown of the vaccination process due to the suspected increased risk of anaphylactic reactions, especially in high-risk patients [ 8 ].…”

Section: Introductionmentioning

confidence: 99%

Safety and Tolerability of COVID-19 Vaccine in Mast Cell Disorders Real-Life Data from a Single Centre in Italy

Nicola,

Mazzola,

Lo Sardo

et al. 2024

Vaccines

View full text Add to dashboard Cite

Background In the past three years, COVID-19 has had a significant impact on the healthcare systems and people’s safety worldwide. Mass vaccinations dramatically improved the health and economic damage caused by SARS-CoV-2. However, the safety of COVID-19 vaccines in patients at high risk of allergic reactions still has many unmet needs that should be clarified. Material and methods A retrospective, single-centre study was performed by collecting demographic and clinical data of patients with Mast Cell Disorders (MCDs) to evaluate the safety and tolerability of COVID-19 vaccinations. Moreover, any changes in the natural history of the underlying disease following the vaccine have been evaluated. Results This study included 66 patients affected with MCDs. Out of them, 52 (78.8%) received a COVID-19 vaccination and 41 (78.8%) completed the vaccination course. Premedication came first in 86.6% of our patients. A total of seven (4.5%) patients complained about an immediate reaction and two (1.3%) had a late reaction. Worsening of MCD history was observed in a single patient. Conclusions Despite the overall high risk of allergic reactions, our study did not reveal any increased risk for SARS-CoV-2 allergic reactions in MCD patients, thus supporting the recommendation in favour of the SARS-CoV-2 vaccination. However, due to the potentially increased rate of anaphylactic reactions, MCD patients should receive vaccine premedication and should be treated in a hospital setting after an allergological specialistic evaluation.

show abstract

SARS-CoV-2 vaccines are well tolerated in patients with mastocytosis

Cited by 6 publications

References 5 publications

COVID-19 Vaccines Are Safely Tolerated in Adolescents with Cutaneous Mastocytosis

COVID-19 Vaccines Are Safely Tolerated in Adolescents with Cutaneous Mastocytosis

Mastocytosis: the safety of different COVID-19 vaccines

Safety and Tolerability of COVID-19 Vaccine in Mast Cell Disorders Real-Life Data from a Single Centre in Italy

Contact Info

Product

Resources

About